Consider the following pharmaceutical competitive intelligence (CI) scenario: You’re racing against 2 competitors to launch a gene therapy drug to treat diabetes. With so much at stake, your marketing VP gives you the green light to set up a CI program to gain a clearer understanding of these competitor threats. Will you obtain the competitive information that you require to make the best strategic business decisions? Although some pharmaceutical CI programs garner just the right competitive intelligence to allow companies to effectively fight back competitive threats, the majority fail. But why do so many attempts by Canadian pharma companies to set up a CI program fail? Wishful thinking, oversimplifying and lacking… Read More
Continue Reading